Department of Molecular Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
Department of Molecular Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan; Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Biochem Biophys Res Commun. 2020 Jul 23;528(2):269-275. doi: 10.1016/j.bbrc.2020.05.091. Epub 2020 May 27.
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease that includes fibroblastic foci (FF). It has been increasingly appreciated that the origin of collagen-overproducing cells such as pathological myofibroblasts in FF is pericytes. However, neither pericytes derived from the lung nor FF in the IPF lung have not been fully characterized. Human lung pericytes (HuL-P) examined in this study expressed two representative pericyte markers; platelet-derived growth factor receptor β (PDGFRB) and chondroitin sulfate proteoglycan 4 (CSPG4), and were able to migrate and cover endothelial tubes in 3D conditions, indicating that they retain characteristics of pericytes. Moreover HuL-P cells transitioned to myofibroblast-like cells in the presence of transforming growth factor (TGF)-β signaling or to pericyte-like cells in the absence of TGF-β signaling (pericyte-myofibroblast transition). On the other hand, the FF detected in this study were invariably localized between peripheral lung epithelia and capillary endothelia, the basement membranes of which are physiologically fused. The localization is highly specific in that the only cells that exist between the gap are pericytes. As expected, FF were immunohistochemically positive for PDGFRB and CSPG4, suggesting that pericytes are activated to form FF. We also found that HuL-P cells were difficult to eradicate by dual silencing of Bcl-xL plus MCL1. It would be more sensible to suppress pericyte-myofibroblast transition than to kill activated myofibroblasts for the treatment of IPF.
特发性肺纤维化 (IPF) 是一种慢性、进行性的肺间质疾病,包括成纤维细胞灶 (FF)。越来越多的人认识到,FF 中胶原过度产生的细胞,如病理性肌成纤维细胞的起源是周细胞。然而,无论是来自肺部的周细胞还是 IPF 肺部的 FF 都没有得到充分的描述。本研究中检查的人肺周细胞 (HuL-P) 表达了两个代表性的周细胞标志物;血小板衍生生长因子受体 β (PDGFRB) 和软骨素硫酸蛋白聚糖 4 (CSPG4),并能够在 3D 条件下迁移并覆盖内皮管,表明它们保留了周细胞的特征。此外,HuL-P 细胞在转化生长因子 (TGF)-β 信号存在的情况下向肌成纤维细胞样细胞转化,或在缺乏 TGF-β 信号的情况下向周细胞样细胞转化 (周细胞-肌成纤维细胞转化)。另一方面,本研究中检测到的 FF 始终定位于外周肺上皮和毛细血管内皮之间,其基底膜在生理上是融合的。这种定位非常特异,因为在间隙之间仅存在周细胞。正如预期的那样,FF 在免疫组织化学上对 PDGFRB 和 CSPG4 呈阳性,这表明周细胞被激活形成 FF。我们还发现,HuL-P 细胞通过双重沉默 Bcl-xL 加 MCL1 很难被根除。对于 IPF 的治疗,抑制周细胞-肌成纤维细胞转化比杀死激活的肌成纤维细胞更明智。